ARTICLE | Deals
Lilly M&A spree now includes $3.8B psychedelics bet on AtaiBeckley
BPL-003 offers a shorter treatment visit, but efficacy and durability advantages over COMP360 remain to be shown
July 16, 2026 10:41 PM UTC
Flush with rapidly growing revenues, Lilly agreed Thursday to acquire AtaiBeckley for up to $3.8 billion, marking its 12th announced acquisition of the year and its entry into psychedelics.
Eli Lilly and Co. (NYSE:LLY) will pay $2.8 billion upfront, or $6.75 per share in cash, to obtain AtaiBeckley Inc. (NASDAQ:ATAI). The deal inclues a CVR worth up to $2.50 per share, or $1 billion in aggregate. The upfront consideration represents a 26% premium to AtaiBeckley’s Wednesday close of $5.36...